Sort
17,828 grants matching “crispr”
Elucidating Context-Specific FERONIA Receptor Kinase Signaling
$368,832Hongqing Guo · Iowa State University · R35 · FY2025 · GM
Investigating imitation SWI chromatin remodeling complexes in mammalian tissue regeneration
$368,813Hao Zhu · Ut Southwestern Medical Center · R01 · FY2021 · DK
Mechanisms of radioresistance and strategies for radiosensitization in OCCC
$368,805Guang Peng · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA
Molecular mechanisms of anterior segment disorders
$368,600Elena V Semina · Medical College Of Wisconsin · R01 · FY2021 · EY
Molecular mechanisms of anterior segment disorders
$368,600Elena V Semina · Medical College Of Wisconsin · R01 · FY2022 · EY
Aging and organismal proteostasis-Project 4 RM
$368,555Richard I. Morimoto · Northwestern University · P01 · FY2020 · AG
Single molecule and biophysical studies of nucleic acid remodeling
$368,438Taekjip Ha · Johns Hopkins University · R35 · FY2022 · GM
Computational Methods for Mapping Genetic Interactions in Human Cells
$368,428Chad L Myers · University Of Minnesota · R01 · FY2021 · HG
Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS
$368,409Thomas Gaj · University Of Illinois At Urbana-Champaign · R01 · FY2023 · NS
A novel more effective genotoxic therapy for ovarian cancer
$368,288Fiona Simpkins · University Of Pennsylvania · R37 · FY2018 · CA
A novel more effective genotoxic therapy for ovarian cancer
$368,288Fiona Simpkins · University Of Pennsylvania · R37 · FY2020 · CA
Wnt signaling in obesity-associated colorectal cancer
$368,288Jatin Roper · Duke University · R37 · FY2025 · CA
A novel more effective genotoxic therapy for ovarian cancer
$368,288Fiona Simpkins · University Of Pennsylvania · R37 · FY2022 · CA
Wnt signaling in obesity-associated colorectal cancer
$368,288Jatin Roper · Duke University · R37 · FY2022 · CA
A novel more effective genotoxic therapy for ovarian cancer
$368,288Fiona Simpkins · University Of Pennsylvania · R37 · FY2021 · CA
Determining the specificity and regulation of Type III CRISPR-Cas interference
$368,258Jack Albert Dunkle · University Of Alabama In Tuscaloosa · R35 · FY2021 · GM
Understanding the neurodevelopmental role and mechanism of histone demethylase JMJD3
$368,139Daniel A Lim · University Of California, San Francisco · R01 · FY2024 · NS
Establishing a Novel Instrumental Model for Elucidating Mitochondrial DNA-Associated Dysfunction and Pathogenicity
$368,006Zengyi Shao · Iowa State University · R35 · FY2022 · GM
LISTERIA MONOCYTOGENES IS A BACTERIAL FOODBORNE PATHOGEN WHICH REMAINS A MAJOR CAUSE OF DEATHS DUE TO FOODBORNE DISEASE IN THE UNITED STATES. INFECTION CAN RESULT IN INVASIVE, SYSTEMIC ILLNESS (LISTERIOSIS) WITH SEVERE SYMPTOMS AND HIGH CASE FATALITY RATE OF APPROXIMATELY 16%, EVEN UNDER APPROPRIATE ANTIMICROBIAL TREATMENT. IT AFFLICTS PRIMARILY INDIVIDUALS SUFFERING FROM SEVERE IMMUNOCOMPROMISING CONDITIONS, THE ELDERLY, AND PREGNANT WOMEN IN WHOM ILLNESS CAN RESULT IN ABORTIONS AND STILLBIRTHS. LISTERIA HAS BECOME NOTORIOUS FOR ITS CAPACITY TO PERSIST IN FOOD PROCESSING ENVIRONMENTS OVER LONG PERIODS OF TIME, SOMETIMES OVER MANY YEARS. IN SPITE OF IMPROVEMENTS IN LISTERIA SURVEILLANCE AND CONTROL, OUTBREAKS OF FOODBORNE LISTERIOSIS AND MULTIPLE FOOD RECALLS CONTINUE TO TAKE PLACE IN THE UNITED STATES AND OTHER INDUSTRIALIZED NATIONS, SUGGESTING THE NEED FOR IMPROVED INTERVENTIONS. IN THIS PROJECT WE WILL TAKE ADVANTAGE OF RECENT ADVANCES IN THE USE OF CRISPR TECHNOLOGY TOWARDS THE GENETIC ENGINEERING OF VIRUSES (ALSO REFERRED TO AS BACTERIOPHAGE OR PHAGE) SPECIFIC FOR LISTERIA. LISTERIA-SPECIFIC PHAGE HAVE THE CAPACITY TO SERVE AS POWERFUL BIOLOGICAL CONTROLS AGAINST LISTERIA, AND HAVE ALREADY GAINED REGULATORY APPROVAL IN THE UNITED STATES FOR THEIR USE IN FOODS AND FOOD PROCESSING ENVIRONMENTS. HOWEVER, THEIR EFFICACY CAN BE COMPROMISED BY THE FACT THAT CERTAIN STRAINS OF LISTERIA, INCLUDING ALL MEMBERS OF A MAJOR CLONAL GROUP IMPLICATED IN NUMEROUS OUTBREAKS, ARE RESISTANT TO PHAGE. WE WILL EMPLOY AN ARRAY OF MOLECULAR BIOLOGIC PROCEDURES TO ENGINEER THE GENOMES OF LISTERIA-SPECIFIC PHAGE SO THAT THEY ENCODE CRISPR SYSTEMS PROGRAMMED TO DEGRADE HIGHLY-CONSERVED GENES OF LISTERIA MONOCYTOGENES, ESSENTIALLY CAUSING LISTERIA TO SELF-DESTRUCT UPON INFECTION BY THE PHAGE. THE CRISPR SYSTEM WILL BE INTRODUCED IN PHAGE GENOMES WHICH WILL BE ADDITIONALLY MODIFIED TO ALLOW MAXIMUM HOST RANGE, SO THAT LISTERIA STRAINS OF DIVERSE SEROTYPES AND GENOTYPES CAN BE EFFECTIVELY INFECTED AND KILLED. SPECIFIC PROCEDURES WILL BE EMPLOYED TO ALLOW THE PHAGE TO EVADE THE RESISTANCE EXHIBITED BY CERTAIN PROBLEMATIC STRAINS OF LISTERIA MONOCYTOGENES. THE ENGINEERED CRISPR-EQUIPPED PHAGES WILL BE VALIDATED AGAINST A LARGE LISTERIA PANEL INCLUDING STRAINS FROM FOOD PROCESSING ENVIRONMENTS, READY-TO-EAT FOODS AND RECENT OUTBREAKS OF HUMAN LISTERIOSIS. WE EXPECT THAT THE ENGINEERED PHAGE WILL SERVE WELL AS A HIGHLY-TARGETED, EFFECTIVE BIOCONTROL TOOL FOR ELIMINATING PERSISTENT LISTERIA MONOCYTOGENES FROM FOOD-PROCESSING ENVIRONMENTS, THUS SIGNIFICANTLY ENHANCING THE SAFETY OF THE FOOD SUPPLY.
$367,899North Carolina State University · · FY2019 · National Institute of Food and Agriculture
The role of gene enhancer elements in colon cancer
$367,814Peter Christopher Scacheri · Case Western Reserve University · R01 · FY2020 · CA
Molecular determinants of neuronal protein homeostasis through plasma membrane-localized proteasome complexes.
$367,800Kapil Ramachandran · Columbia University Health Sciences · DP5 · FY2021 · OD
The role of AU-rich element binding proteins in shaping target mRNA expression
$367,727Markus Hafner · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2017 · AR
Investigating imitation SWI chromatin remodeling complexes in mammalian tissue regeneration
$367,688Hao Zhu · Ut Southwestern Medical Center · R01 · FY2020 · DK
Pathophysiology of DYT1 dystonia: Targeted Mouse Models
$367,646Yuqing Li · University Of Florida · R01 · FY2025 · NS
Transcriptional and epigenetic mechanisms of immunotherapy resistance in melanoma
$367,559Kai W Wucherpfennig · Massachusetts General Hospital · P01 · FY2020 · CA